A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)

Summary

This is a Phase III, randomized, double blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of ocrelizumab compared to placebo when combined with a single stable background immunosuppressive medication and a corticosteroid regimen in patients with moderately to severely active systemic lupus erythematosus, who do not have moderate to severe glomerulonephritis.

Timeline

Start

2007-12-19

Primary completion

2011-07-12

Completion

2011-07-12

Outcome

Outcome not reported

Stopped: “The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.”

Drugs

Indications